InMed Pharmaceuticals Inc. reported a direct stock-option award to director Michelle Patricia Pernice: 37,000 options on November 9, 2026. Each option represents the right to purchase one common share at an exercise price of $16 per share. The options expire November 9, 2036, and her reported position following the award was 37,000 options.
InMed Pharmaceuticals Inc. (INM) director Todd Shegog received an option award on November 9, 2026, covering the right to purchase 37,000 common shares at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to his continued service on each vesting date, and expire November 9, 2036.
InMed Pharmaceuticals Inc. (INM) reports that President and Chief Executive Officer Gregory J. Divis directly holds options to purchase 1,454,398 common shares at an exercise price of $10.37 per share, expiring September 24, 2036. Effective November 6, 2026, the options were received in the merger in exchange for options in Pre-Merger Mentari.
InMed Pharmaceuticals Inc. reports that Brett R. Hagen, its Senior Vice President, Finance and Chief Accounting Officer, directly holds options to purchase 62,273 shares of common stock at an exercise price of $10.37 per share, expiring September 24, 2036. The options were received in the merger effective November 6, 2026, in exchange for options in Pre-Merger Mentari. They vest as to 25% on August 3, 2027, with equal monthly installments thereafter through August 3, 2030, subject to his continued service on each vesting date.
InMed Pharmaceuticals Inc. officer Jerad G. Seurer reported a direct option position covering 93,411 common shares, received in the November 6, 2026 merger in exchange for options he held in Pre-Merger Mentari. The options have a $10.37 exercise price and expire September 24, 2036. Twenty-five percent vests August 3, 2027, with equal monthly installments thereafter through August 3, 2030, subject to his continued service on each vesting date.
InMed Pharmaceuticals Inc. (INM) reports that Fairmount Healthcare Fund II L.P. indirectly held 10,555,507 common shares as of November 6, 2026, following a merger exchange effective that day. The fund also held 4,013 shares of Series A non-voting convertible preferred stock representing 4,013,000 underlying common shares, plus pre-funded warrants for 1,468,222 common shares exercisable at $0.0001 each.
Fairmount Funds Management LLC, Peter Evan Harwin and Tomas Kiselak are also identified as ten-percent owners. They disclaim beneficial ownership except to the extent of their pecuniary interest. The preferred stock and warrants carry 19.99% beneficial-ownership limits; the preferred-stock limit automatically becomes 9.99% when ownership is 9.00% or less.
InMed Pharmaceuticals Inc. (INM) identifies Todd Shegog as a director in a Form 3 ownership filing.
InMed Pharmaceuticals Inc. director Michelle Patricia Pernice reported direct holdings of 27,868 common shares following the merger effective November 6, 2026. The shares were received in exchange for her Pre-Merger Mentari common shares. Of the reported shares, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to continued service on each vesting date.
InMed Pharmaceuticals Inc. director Julianne Bruno reported a direct holding of 33,442 common shares following the November 6, 2026 merger. She received the shares in exchange for Pre-Merger Mentari common shares she held before the merger. Of the reported shares, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to her continued service.